palmitoylethanolamide.com.au
HomeResearchKriek 2014

Marketing messages in pharmacological papers and scientific chapters: the case of palmitoylethanolamide and its formulations

Kriek R. Pharmacol Res. 2014;85:1-3.

ReviewHumans

Design
Review
Subjects
Letter to the editor
Dose used in the study
Not applicable
Duration
Not applicable
What was measured
A critique of how branded micronised and ultramicronised formulations are presented in pharmacology papers and book chapters

What the authors reported

The author argues that some scientific papers on palmitoylethanolamide carry marketing messages for particular formulations. A reply from Cuzzocrea was published in the same journal (PMID 24852086). A second letter by the same author in Pain, 2016, made a similar point about a branded name in an animal study (PMID 26871399).

Limits of this study

Opinion letters, not data. Listed so readers know that the formulation claims discussed on this site have been publicly disputed within the literature. Read with the replies.

Source

PubMed 24769196 · doi:10.1016/j.phrs.2014.04.007

Entry checked against the PubMed record; letters have no abstract on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.